BioInformant

Your Global Leader in Stem Cell Market Research

Home » Interviews » Page 2

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Behind the Scenes at Cynata Therapeutics with Dr. Ross Macdonald

By

Cynata TherapeuticsCynata Therapeutics Ltd (ASX: CYP) is a clinical stage regenerative medicine company specializing in stem cell therapeutics that has a proprietary technology for manufacturing induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (MSCs).

I had the honor of interviewing Dr Ross Macdonald, CEO of Cynata Therapeutics. In this interview, we discuss Cynata’s technology platform, the company’s world first achievements, and its clinical trial underway for GvHD. We also explore the company’s strategic goals and the importance of its partnership with Fujifilm in Japan. [Read more…]

Introducing the Dawn of MSCs with RoosterBio Founder, Jon Rowley

By

RoosterBioFounded by Dr. Jon Rowley, RoosterBio is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. I had the honor of interviewing Dr. Jon Rowley, who is now the CTO of RoosterBio.

In this interview, we explore RoosterBio’s recent product launches, collaborations, achievements and future trajectory.    [Read more…]

Cord Blood Market Consolidation in Latin America

By

CryoHoldcoIn this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco.

Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America.

CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America. In this interview, we discuss the current and future state of cord blood banking within Latin America, Cryoholdco’s role within this evolving marketplace, and future directions for the company.

Prior to initiating the consolidation strategy of CryoHoldco with ACON Investments, Alexis was a Director of TCP Latam, a private equity and restructuring fund in Brazil.  Prior to TCP Latam, he was a senior associate at Long Point Capital, a leveraged-buyout private equity fund in New York, where Alexis was responsible for equity investments in excess of USD $100 million in several private companies.

[Read more…]

Interview With Kaz Hirao, CEO Of Cellular Dynamics International (CDI)

By

Cellular Dynamics International (CDI), a FUJIFILM company, is thCellular Dynamics FUJIFILM | Interview with Kaz Hirao, CEO of Cellular Dynamics International (CDI)e largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI recently divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics. As featured in the company motto, CDI is now positioned to facilitate “Endless Possibilities from Discovery to Regenerative Medicine.”

In this article:

[Read more…]

Rhemastem, Leveraging Stem Cells from Solid Tumors in the Race to Cure Colorectal Cancer

By

Headquartered in Monza, Italy, RhemaStem is a unique biotech company that specializes in developing innovative and effective drugs for colorectal cancer and other solid cancers. The company’s mission is to cure colorectal cancer and other solid cancers using its expertise in the area of cancer and normal stem cells. I had the distinct honour of interviewing Dr. Zeni of RhemaStem.

In this interview, we explore the founding of Rhemstem, its unique technology platform, intellectual property (IP), future directions, and more. Enjoy! [Read more…]

BioInformant's World-Class Clients